Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Ann Hematol ; 81(7): 357-61, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12185503

RESUMO

Monoclonal gammopathy of undetermined significance (MGUS) is a relatively common condition among individuals older than 70 years. The actuarial risk of MGUS progression to an overt plasma cell malignancy (PCM) after 20 years of follow-up has been reported to be as high as 30%. The purpose of this study was to evaluate the incidence and evolution of MGUS in a Greek population: 1564 consecutive patients older than 50 years who were admitted to the Department of Clinical Therapeutics at the University of Athens School of Medicine for various reasons over a 26-month period were evaluated with serum protein electrophoresis. In cases in which a monoclonal protein was detected, a panel of tests was performed to rule out an underlying plasma cell malignancy (PCM). Serum levels of interleukin (IL)-6, IL-6-soluble receptor (IL-6SR), IL-1 beta, and transforming growth factor beta 1 were also measured in the MGUS cases. Patients with MGUS were monitored at regular intervals for evidence of multiple myeloma or other PCMs. The incidence of MGUS was 4% and there was a positive correlation with increasing age. The median value of serum M peak was only 5.3 g/l. After a median follow-up of 71 months, only two patients developed multiple myeloma (60 and 75 months after initial diagnosis). Our data are consistent with those of other epidemiological studies regarding the incidence of MGUS, but the monoclonal protein levels and the probability of evolution to a malignant plasma cell disorder appeared to be lower in our study than in other series. Our data support the hypothesis that individuals with low M peak values require only regular annual follow-up examinations.


Assuntos
Gamopatia Monoclonal de Significância Indeterminada/complicações , Gamopatia Monoclonal de Significância Indeterminada/epidemiologia , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Proteínas Sanguíneas/análise , Citocinas/sangue , Progressão da Doença , Feminino , Grécia/epidemiologia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Gamopatia Monoclonal de Significância Indeterminada/sangue , Mieloma Múltiplo/epidemiologia , Mieloma Múltiplo/etiologia , Paraproteínas/análise , Distribuição por Sexo
2.
Eur J Epidemiol ; 12(3): 297-301, 1996 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8884198

RESUMO

Aim of the study was to record the prevalence of the various types of viral hepatitis, especially hepatitis B, in pregnant Albanian refugees in Greece. The study comprised 500 pregnant refugees of mean age 25.1 +/- 4.6 years. In Albania, all women had lived in overcrowded houses and had been exposed to non throw-away needles and syringes. Various indices for all hepatitis types were determined. The prevalence of HBsAg was 13.4%, of anti-HBs 53%, of total anti-HBc 70.8%, of anti-HBc IgM 0.4%, of HBeAg 1.2%, of anti-HBe 58.6%, of anti-HAV 96.2%, of anti-HAV IgM 1%, of anti-HDV 0.4%, of anti-HCV 0.6% and of anti-HEV 2%. HBeAg was found positive in 7.5% of HBsAg carriers. Prevalence of hepatitis B markers, as determined by HBsAg and/or anti-HBs and/or total anti-HBc was significantly higher in those with a history of previous hospitalization in Albania (p = 0.01) and those with previous history of hepatitis (p = 0.02). The high prevalence of hepatitis B markers in pregnant Albanian refugees proves that HBV infection is highly endemic in Albania and the possibility of perinatal transmission to the offsprings urges for HBV vaccination programmes. On the other hand improvements in the socioeconomic conditions and the sanitation system in Albania is anticipated to reduce the incidence of HAV and HBV infections.


Assuntos
Anticorpos Anti-Hepatite/sangue , Antígenos de Hepatite/sangue , Hepatite/epidemiologia , Complicações Infecciosas na Gravidez/epidemiologia , Refugiados/estatística & dados numéricos , Adolescente , Adulto , Albânia/etnologia , Biomarcadores , Distribuição de Qui-Quadrado , Feminino , Grécia/epidemiologia , Grécia/etnologia , Hepatite/virologia , Hepatite A/epidemiologia , Hepatite A/virologia , Hepatite B/epidemiologia , Hepatite B/virologia , Humanos , Gravidez , Complicações Infecciosas na Gravidez/virologia , Recidiva
4.
J Clin Endocrinol Metab ; 57(4): 859-62, 1983 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-6309889

RESUMO

Iodized oil (1 ml im) was given to 58 goitrous patients from a mildly iodine-deficient area in Greece. Goiter size, urinary iodine, and serum T4, T3RU, T3, rT3, TSH, thyroxine-binding globulin (TBG), and thyroid autoantibodies were measured before and 1, 3, and 6 months after the injection. Goiter size decreased. Serum T4 remained relatively constant, but TBG decreased and therefore T3RU and FTI increased. Serum T3 and rT3 initially decreased (P less than 0.001) and then increased at the sixth month (P less than 0.001), both showing roughly parallel changes. Serum TSH, initially normal (1.42 +/- 0.11 (SEM) mU/liter), decreased to 0.65 +/- 0.01 and 0.76 +/- 0.05 mU/liter at the third and sixth month (difference from baseline P less than 0.001). Thyroid autoantibodies, both against thyroglobulin and the microsomal antigen, were undetectable before treatment, but became positive in 42.8% of the patients 3 and 6 months later. Three patients developed transient hyperthyroidism. This occurred 3 or 6 months after treatment, and was associated with high titers of thyroid autoantibodies. These results indicate that: 1) transient hyperthyroidism may occur after the administration of iodized oil, possibly because of thyroid tissue necrosis and leakage of hormones, and 2) serum TBG decreases after iodized oil, a finding not previously reported and one whose cause is not known.


Assuntos
Autoanticorpos/análise , Bócio Endêmico/imunologia , Hormônios Tireóideos/sangue , Adulto , Feminino , Bócio Endêmico/tratamento farmacológico , Humanos , Hipertireoidismo/induzido quimicamente , Óleo Iodado/efeitos adversos , Óleo Iodado/uso terapêutico , Masculino , Pessoa de Meia-Idade , Hormônios Tireóideos/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA